Literatur
- 1
Windecker S, Meier B.
Intervention in coronary artery disease.
Heart.
2000;
83
481-490
- 2
Serruys P W, Kutryk M J, Ong A T.
Coronary-artery stents.
N Engl J Med.
2006;
354
483-495
- 3
Silber S, Borggrefe M, Böhm M. et al .
Positionspapier der DGK zur Wirksamkeit und Sicherheit von Medikamente freisetzenden
Koronarstents (DES). Eine evidenzbasierte Analyse von 71 randomisierten Studien mit
28 984 Patienten.
Der Kardiologe.
2007;
1
84-111
- 4
Kastrati A, Dibra A, Eberle S. et al .
Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery
disease: meta-analysis of randomized trials.
Jama.
2005;
294
819-825
- 5
Schuhlen H, Kastrati A, Dirschinger J. et al .
Intracoronary stenting and risk for major adverse cardiac events during the first
month.
Circulation.
1998;
98
104-111
- 6
Ong A T, Hoye A, Aoki J. et al .
Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion
after bare-metal, sirolimus, or paclitaxel stent implantation.
J Am Coll Cardiol.
2005;
45
947-953
- 7
Camenzind E, Steg P G, Wijns W.
Stent thrombosis late after implantation of first-generation drug-eluting stents:
a cause for concern.
Circulation.
2007;
115
1440-1455; discussion 1455
- 8
Pfisterer M, Brunner-La R occa, Buser P T. et al .
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting
stents: an observational study of drug-eluting versus bare-metal stents.
J Am Coll Cardiol.
2006;
48
2584-2591
- 9
Bavry A A, Kumbhani D J, Helton T J. et al .
Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials.
Am J Med.
2006;
119
1056-1061
- 10
Daemen J, Wenaweser P, Tsuchida K. et al .
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting
stents in routine clinical practice: data from a large two-institutional cohort study.
Lancet.
2007;
369
667-678
- 11
Wenaweser P, Rey C, Eberli F R. et al .
Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous
coronary intervention and predictors of adverse outcome.
Eur Heart J.
2005;
26
1180-1187
- 12
Wenaweser P, Dorffler-Melly J, Imboden K. et al .
Stent thrombosis is associated with an impaired response to antiplatelet therapy.
J Am Coll Cardiol.
2005;
45
1748-1752
- 13
Iakovou I, Schmidt T, Bonizzoni E. et al .
Incidence, predictors, and outcome of thrombosis after successful implantation of
drug-eluting stents.
Jama.
2005;
293
2126-2130
- 14
Kuchulakanti P K, Chu W W, Torguson R. et al .
Correlates and long-term outcomes of angiographically proven stent thrombosis with
sirolimus- and paclitaxel-eluting stents.
Circulation.
2006;
113
1108-1113
- 15
Rodriguez A E, Mieres J, Fernandez-Pereira C. et al .
Coronary stent thrombosis in the current drug-eluting stent era: insights from the
ERACI III trial.
J Am Coll Cardiol.
2006;
47
205-207
- 16
McFadden E P, Stabile E, Regar E. et al .
Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet
therapy.
Lancet.
2004;
364
1519-1521
- 17
Farb A, Burke A P, Kolodgie F D, Virmani R.
Pathological mechanisms of fatal late coronary stent thrombosis in humans.
Circulation.
2003;
108
1701-1706
- 18
Moreno R, Fernandez C, Hernandez R. et al .
Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized
studies.
J Am Coll Cardiol.
2005;
45
954-959
- 19
Virmani R, Guagliumi G, Farb A. et al .
Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting
stent: should we be cautious?.
Circulation.
2004;
109
701-705
- 20
Nebeker J R, Virmani R, Bennett C L. et al .
Hypersensitivity cases associated with drug-eluting coronary stents: a review of available
cases from the Research on Adverse Drug Events and Reports (RADAR) project.
J Am Coll Cardiol.
2006;
47
175-181
- 21
Joner M, Finn A V, Farb A. et al .
Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.
J Am Coll Cardiol.
2006;
48
193-202
- 22
Kotani J, Awata M, Nanto S. et al .
Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings.
J Am Coll Cardiol.
2006;
47
2108-2111
- 23
Cook S, Wenaweser P, Togni M. et al .
Incomplete stent apposition and very late stent thrombosis after drug-eluting stent
implantation.
Circulation.
2007;
115
2426-2434
- 24
Nordmann A J, Briel M, Bucher H C.
Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents
in coronary artery disease: a meta-analysis.
Eur Heart J.
2006;
27
2784-2814
- 25
Stone G W, Moses J W, Ellis S G. et al .
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
N Engl J Med.
2007;
356
998-1008
- 26
Kastrati A, Mehilli J, Pache J. et al .
Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.
N Engl J Med.
2007;
356
1030-1039
- 27
Sousa J E, Morice M C, Serruys P W.
The RAVEL study: a randomized study with the sirolimus balloon-expandable stent in
the treatment of patients with de novo native coronary artery lesions (Abstract).
Circulation.
2001;
104 Suppl II
17
- 28
Sousa J E, Costa M A, Sousa A G. et al .
Two-year angiographic and intravascular ultrasound follow-up after implantation of
sirolimus-eluting stents in human coronary arteries.
Circulation.
2003;
107
381-383
- 29
Lagerqvist B, James S K, Stenestrand U. et al .
Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.
N Engl J Med.
2007;
356
1009-1019
- 30
Meier P, Zbinden R, Togni M. et al .
Coronary collateral function long after drug-eluting stent implantation.
J Am Coll Cardiol.
2007;
49
15-20
- 31
Togni M, Windecker S, Cocchia R. et al .
Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction.
J Am Coll Cardiol.
2005;
46
231-236
- 32
Togni M, Raber L, Cocchia R. et al .
Local vascular dysfunction after coronary paclitaxel-eluting stent implantation.
Int J Cardiol.
2007;
120
212-220
- 33
Hofma S H, van der Giessen W J, van Dalen B M. et al .
Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation.
Eur Heart J.
2006;
27
166-170
- 34 NICE .Ischaemic heart disease - coronary artery stents (review): appraisal consultation
document. Committee’s preliminary recommendations: Drug-eluting stents are not recommended
for use in percutaneous coronary intervention in patients with coronary artery disease. http://www.nice.org.uk 2007
- 35
vom Dahl J, Haager P K, Grube E. et al .
Effects of gold coating of coronary stents on neointimal proliferation following stent
implantation.
Am J Cardiol.
2002;
89
801-805
- 36
Kastrati A, Schomig A, Dirschinger J. et al .
Increased risk of restenosis after placement of gold-coated stents: results of a randomized
trial comparing gold-coated with uncoated steel stents in patients with coronary artery
disease.
Circulation.
2000;
101
2478-2483
- 37
Cutlip D E, Baim D S, Ho K K. et al .
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent
clinical trials.
Circulation.
2001;
103
1967-1971
- 38
Aoki J, Serruys P W, van Beusekom H. et al .
Endothelial progenitor cell capture by stents coated with antibody against CD34: the
HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First
In Man) Registry.
J Am Coll Cardiol.
2005;
45
1574-1579
- 39
Windecker S, Simon R, Lins M. et al .
Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel
stent for coronary revascularization: the TiNOX trial.
Circulation.
2005;
111
2617-2622
- 40
Windecker S, Billinger M, Hess O M.
Stent coating with titanium-nitride-oxide for prevention of restenosis. Editorial.
EuroInterv.
2006;
2
146-148
- 41
Yeh H I, Lu S K, Tian T Y. et al .
Comparison of endothelial cells grown on different stent materials.
J Biomed Mater Res A.
2006;
76
835-841
- 42
Zhang F, Zheng Z, Chen Y. et al .
In vivo investigation of blood compatibility of titanium oxide films.
J Biomed Mater Res A.
1998;
42
128-133
- 43
Steinemann S G.
Titanium: the material of choice?.
Periodontology.
2000;
17
7-21
- 44
Awata M, Kotani J I, Uematsu M. et al .
Serial Angioscopic Evidence of Incomplete Neointimal Coverage After Sirolimus-Eluting
Stent Implantation. Comparison With Bare-Metal Stents.
Circulation.
2007;
116
910-916
- 45
Serruys P W, Sianos G, Abizaid A. et al .
The effect of variable dose and release kinetics on neointimal hyperplasia using a
novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution
Study (PISCES).
J Am Coll Cardiol.
2005;
46
253-260
Prof. Dr. Otto Hess
Schweizer Herz- und Gefäßzentrum
Inselspital
CH-3010 Bern
Email: otto.hess@insel.ch
